ThinkstockAny time that you hear about new drugs and medical treatments, they tend to be around ongoing treatments rather than cures. And when it comes to AIDS and HIV, the past has been cruel…
Among speculative small-cap biotechs, analyst calls are often accompanied with upside price targets of 50%, 100% or even 200%. This is because the companies are often all-in bets on one or two treatments.
Biotech company MannKind reported its first-quarter financial results after the markets closed Thursday.
In a new report, the RBC team focused on the companies that are making the most progress with treatments for patients with breast cancer.
A new research note from SunTrust Robinson Humphrey mentions four stocks that they think could possibly get swept up in the biotech M&A excitement.
Wednesday morning, PlasmaTech Bio announced that it has entered into a definitive agreement to acquire Abeona Therapeutics.
In a new report, Deutsche Bank acknowledges that while the industry has shown recent weakness, now may be just the right time to add biotech stocks.
Biotech giant Alexion Pharmaceuticals announced Wednesday morning that it will acquire Synageva BioPharma.
Credit Suisse has released a report that detailed its top picks for pharmaceutical stocks for the rest of 2015.
Array BioPharma released disappointing fiscal third-quarter earnings before the markets opened Monday morning.
In a new report, the analysts at Stifel are very positive on two companies leading the charge against antibiotic-resistant "super bugs."
Immunomedics may be poised to make big moves going forward in 2015, according to Wells Fargo.
Recently, biotech stocks have been getting stung pretty good, and now may be a good time to look at companies with pending catalysts.
Gilead Sciences reported better than expected first-quarter results Thursday after the markets closed.
A lot of times when companies have secondary offerings the price takes a slight dip to accommodate the dilution and price. However a landslide drop of almost 15% is not often in the cards.